Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366176163> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4366176163 endingPage "S79" @default.
- W4366176163 startingPage "S79" @default.
- W4366176163 abstract "Omalizumab is a anti-IgE monoclonal antibody approved for patients with chronic spontaneous urticaria (CSU), but no serum marker is well-established for predicting clinical response to omalizumab. The aim of this study was to elucidate the association between pre-treatment total serum IgE levels and the clinical efficacy of omalizumab for CSU. We performed a systematic review for relevant studies in electronic databases of PubMed, Web of Science, Scopus, and Cochrane Library from inception to August 23, 2022. No language restrictions were applied. A random-effects model was adopted for meta-analysis. Finally, ten interventional studies, including one randomized controlled trial, were included in the meta-analysis, and a total of 866 patients with CSU were enrolled. The pooled estimates demonstrated significantly higher serum total IgE levels in complete responders (CRs) than in nonresponders (NRs) (mean difference [MD]: 56.509 IU/mL;P = .001) and in partial responders (PRs) than in NRs (MD: 62.688 IU/mL; P < .001), but the difference between CRs and PRs was not significant. The mean total IgE levels for CRs, PRs, and NRs were 163.154, 179.926, and 51.535 IU/mL, respectively. Furthermore, the meta-analysis showed early CRs had significantly higher serum total IgE levels than those in late CRs (MD: 55.194 IU/mL; P= .010). The sensitivity analyses exhibited the robustness of all findings. This systematic review and meta-analysis provides convincing evidence that serum total IgE levels prior to administration of omalizumab are a predictor for the clinical response to omalizumab in patients with CSU." @default.
- W4366176163 created "2023-04-19" @default.
- W4366176163 creator A5007234996 @default.
- W4366176163 creator A5035921369 @default.
- W4366176163 creator A5043550707 @default.
- W4366176163 creator A5075620683 @default.
- W4366176163 date "2023-05-01" @default.
- W4366176163 modified "2023-09-28" @default.
- W4366176163 title "461 Total serum IgE levels as a predictor for clinical response to omalizumab in patients with chronic spontaneous urticaria: A systematic review and meta-analysis" @default.
- W4366176163 doi "https://doi.org/10.1016/j.jid.2023.03.467" @default.
- W4366176163 hasPublicationYear "2023" @default.
- W4366176163 type Work @default.
- W4366176163 citedByCount "0" @default.
- W4366176163 crossrefType "journal-article" @default.
- W4366176163 hasAuthorship W4366176163A5007234996 @default.
- W4366176163 hasAuthorship W4366176163A5035921369 @default.
- W4366176163 hasAuthorship W4366176163A5043550707 @default.
- W4366176163 hasAuthorship W4366176163A5075620683 @default.
- W4366176163 hasBestOaLocation W43661761631 @default.
- W4366176163 hasConcept C126322002 @default.
- W4366176163 hasConcept C141105273 @default.
- W4366176163 hasConcept C159654299 @default.
- W4366176163 hasConcept C168563851 @default.
- W4366176163 hasConcept C203014093 @default.
- W4366176163 hasConcept C2776478404 @default.
- W4366176163 hasConcept C2778564945 @default.
- W4366176163 hasConcept C3020774429 @default.
- W4366176163 hasConcept C535046627 @default.
- W4366176163 hasConcept C71924100 @default.
- W4366176163 hasConcept C90924648 @default.
- W4366176163 hasConcept C95190672 @default.
- W4366176163 hasConceptScore W4366176163C126322002 @default.
- W4366176163 hasConceptScore W4366176163C141105273 @default.
- W4366176163 hasConceptScore W4366176163C159654299 @default.
- W4366176163 hasConceptScore W4366176163C168563851 @default.
- W4366176163 hasConceptScore W4366176163C203014093 @default.
- W4366176163 hasConceptScore W4366176163C2776478404 @default.
- W4366176163 hasConceptScore W4366176163C2778564945 @default.
- W4366176163 hasConceptScore W4366176163C3020774429 @default.
- W4366176163 hasConceptScore W4366176163C535046627 @default.
- W4366176163 hasConceptScore W4366176163C71924100 @default.
- W4366176163 hasConceptScore W4366176163C90924648 @default.
- W4366176163 hasConceptScore W4366176163C95190672 @default.
- W4366176163 hasIssue "5" @default.
- W4366176163 hasLocation W43661761631 @default.
- W4366176163 hasOpenAccess W4366176163 @default.
- W4366176163 hasPrimaryLocation W43661761631 @default.
- W4366176163 hasRelatedWork W2806018152 @default.
- W4366176163 hasRelatedWork W3009029583 @default.
- W4366176163 hasRelatedWork W3047565151 @default.
- W4366176163 hasRelatedWork W3152374296 @default.
- W4366176163 hasRelatedWork W3197582657 @default.
- W4366176163 hasRelatedWork W3213074919 @default.
- W4366176163 hasRelatedWork W4207070666 @default.
- W4366176163 hasRelatedWork W4225274252 @default.
- W4366176163 hasRelatedWork W4309875107 @default.
- W4366176163 hasRelatedWork W4368364040 @default.
- W4366176163 hasVolume "143" @default.
- W4366176163 isParatext "false" @default.
- W4366176163 isRetracted "false" @default.
- W4366176163 workType "article" @default.